EUVIMEDEUVIMED entdecken
Crossref

Serum ADAMTS-9 Level in Newborn Babies with Congenital Heart Disease

Cem Becerir iD, Cüneyt Tayman iD, Abdullah Kurt iD, Ufuk Çakır iD, İsmail Koyuncu iD, Burak Ceran iD, Kenan Toprak iD, Murat Kızılgün iD

American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e2555-e2561

DOI: 10.1055/a-2125-1330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Cem Becerir und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Ankara City Hospital, Neonatal Intensive Care Unit, University of Health Sciences, Ankara, Turkey. Hauptthemen laut MEDLINE: Heart Defects, Congenital, ADAMTS9 Protein, Biomarkers. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A Disintegrin and Metalloproteinase with Thrombospondin-9 (ADAMTS-9), one of the ADAMTS enzymes, is expressed in all fetal tissues, unlike other ADAMTS enzymes, and is thus thought to play a role in fetal development. In this context, the objective of this study is to investigate the relationship between ADAMTS-9 activity and the development of congenital heart diseases (CHD) with a view to using ADAMTS-9 level as a biomarker for CHDs. Study Design Newborns diagnosed with CHD and healthy newborns were included in the study as the CHD and control groups, respectively. Gestational age, maternal age, and mode of delivery information pertaining to the mothers and Apgar score and birthweight information pertaining to the newborns were recorded. Blood samples were taken from all newborns to determine their ADAMTS-9 levels in the first 24 hours of life.

Results

Fifty-eight newborns with CHD and 46 healthy newborns were included in the study. Median ADAMTS-9 levels were 46.57 (interquartile range [IQR]: 33.31 [min: 26.92, max: 124.25]) and 23.36 (IQR: 5.48 [min: 11.7, max: 37.71]) ng/mL in the CHD and control groups, respectively. ADAMTS-9 levels in the CHD group were statistically significantly higher than in the control group (p = 0.000). ADAMTS-9 levels of the CHD and control groups were analyzed by the receiver operating characteristics curve. The area under the curve value for ADAMTS-9 levels of >27.86 ng/mL as the cut-off value for predicting the development of CHD in newborns was 0.836 (95% confidence interval [CI]: 0.753–0.900, p = 0.0001). ADAMTS-9 levels of >27.86 ng/mL were determined to predict the development of CHD in newborns with a sensitivity of 77.78% (95% CI: 65.5–87.38) and a specificity of 84.78% (95% CI: 71.1–93.60).

Conclusion

In conclusion, it was found that the serum ADAMTS-9 levels were significantly higher in newborns with CHD than in healthy newborns. In parallel, ADAMTS-9 levels above a certain cut-off value were associated with CHD. Key Points

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Defects, CongenitalADAMTS9 ProteinBiomarkersHumansInfant, NewbornFemaleMaleCase-Control StudiesGestational AgeROC Curve

Substanzen

ADAMTS9 ProteinBiomarkersADAMTS9 protein, human

Autor:innen und Institutionen

  • Department of Neonatology, Ankara City Hospital, Neonatal Intensive Care Unit, University of Health Sciences, Ankara, Turkey.
  • Department of Neonatology, Yildirim Beyazit University Faculty of Medicine, Ankara Turkey.
  • Department of Medical Biochemistry, Harran University, Urfa, Turkey.
  • Cardiology Department, Faculty of Medicine, Harran University, Şanlıurfa, Turkey.
  • Department of Medical Biochemistry, Sağlık Bilimleri Üniversitesi Gülhane Tıp Fakültesi, Health Science University Ankara, Turkey.

ORCID-Profile: Cem Becerir, Cüneyt Tayman, Abdullah Kurt, Ufuk Çakır, İsmail Koyuncu, Burak Ceran, Kenan Toprak, Murat Kızılgün

Zitieren

APA

Becerir, C., Tayman, C., Kurt, A., Çakır, U., Koyuncu, İ., Ceran, B., Toprak, K., & Kızılgün, M. (2024). Serum ADAMTS-9 Level in Newborn Babies with Congenital Heart Disease. American Journal of Perinatology, 41(S 01 S 01), e2555-e2561. https://doi.org/10.1055/a-2125-1330

Vancouver

Becerir C, Tayman C, Kurt A, Çakır U, Koyuncu İ, Ceran B, et al. Serum ADAMTS-9 Level in Newborn Babies with Congenital Heart Disease. American Journal of Perinatology. 2024;41(S 01 S 01):e2555-e2561. doi:10.1055/a-2125-1330

BibTeX
@article{Becerir2024,
  author = {Becerir, Cem and Tayman, Cüneyt and Kurt, Abdullah and Çakır, Ufuk and Koyuncu, İsmail and Ceran, Burak and Toprak, Kenan and Kızılgün, Murat},
  title = {Serum ADAMTS-9 Level in Newborn Babies with Congenital Heart Disease},
  journal = {American Journal of Perinatology},
  year = {2024},
  volume = {41},
  number = {S 01 S 01},
  pages = {e2555--e2561},
  doi = {10.1055/a-2125-1330}
}
Kostenlos starten →